Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
因塞特(US:INCY) Businesswire·2025-12-22 07:42公司动态 - Incyte日本公司宣布其药物Zynyz® (retifanlimab) 获得批准，用于晚期肛门癌的一线治疗 [1] 产品与研发 - 获批药物为retifanlimab，商品名为Zynyz® [1] - 该药物获批的适应症为晚期肛门癌的一线治疗 [1]